Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Sep 16 - Sep 21
glp-1 dental issues ADA adds mental health, questions to health history forms Lilly, Gilead lead pharma's New Arrivals_New Arrivals Protein-Flavor:Chocolate
Lilly, Gilead lead pharma's M&A boom | BioPharma Dive
📖 Show Segments 00:03 - Introduction 01:19 - Exploring GLP-1RA in the News 02:49 - Scientific Background of GLP-1 RA 05:38 - Current Research on Semaglutide 07:13 - Study Design and Methodology 10:38 - Potential Applications of GLP-1RA Beyond Alcohol Use Disorder 12:15 - Challenges in Integrating GLP-1RA into Addiction Care 15:16 - Practical Steps for Addiction Care Providers 18:19 – Looking to the Future 19:27 – Conclusion and Additional Learning Opportunities 📋 Key Takeaways Semaglutide, a GLP-1RA, is currently being studied as a potential adjunctive therapy for alcohol use disorder
New Arrivals_New Arrivals
Protein-Flavor:Chocolate
After scrapping a Biden-era plan to cover obesity drugs in early 2025, the Trump administration reversed course: it struck deals with Novo Nordisk and Eli Lilly in November 2025 to cut GLP-1 prices, and a voluntary Medicare demonstration begins July 1, 2026 that lets participating drug plans cover GLP-1s for weight loss with a $50 monthly copay
US$ 20.82
US$ 29.81
US$ 20.36
US$ 20.87
US$ 28.15
US$ 28.59
US$ 25.94
US$ 24.73
US$ 24.77
